Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key
regulator of bile acid synthesis and transport. Bile acids are used by the body to help with
digestion. Conventional therapy with obecholic acid will improve liver function of patients
with (primary biliary cholangitis)PBC.
The main objectives of the study were to assess the effects of Obeticholic Acid (OCA) on
serum alkaline phosphatase (ALP) and total bilirubin, together as a composite endpoint and on
safety in participants with PBC.